211 related articles for article (PubMed ID: 12917424)
21. Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate.
Carroll SS; Geib J; Olsen DB; Stahlhut M; Shafer JA; Kuo LC
Biochemistry; 1994 Mar; 33(8):2113-20. PubMed ID: 7509634
[TBL] [Abstract][Full Text] [Related]
22. Implication of the tRNA initiation step for human immunodeficiency virus type 1 reverse transcriptase in the mechanism of 3'-azido-3'-deoxythymidine (AZT) resistance.
Vaccaro JA; Anderson KS
Biochemistry; 1998 Oct; 37(40):14189-94. PubMed ID: 9760256
[TBL] [Abstract][Full Text] [Related]
23. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.
Krebs R; Immendörfer U; Thrall SH; Wöhrl BM; Goody RS
Biochemistry; 1997 Aug; 36(33):10292-300. PubMed ID: 9254628
[TBL] [Abstract][Full Text] [Related]
24. Nucleocapsid Protein Precursors NCp9 and NCp15 Suppress ATP-Mediated Rescue of AZT-Terminated Primers by HIV-1 Reverse Transcriptase.
Árquez MA; Martín-Alonso S; Gorelick RJ; Scott WA; Acosta-Hoyos AJ; Menéndez-Arias L
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32747359
[TBL] [Abstract][Full Text] [Related]
25. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
26. Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.
Schneider A; Corona A; Spöring I; Jordan M; Buchholz B; Maccioni E; Di Santo R; Bodem J; Tramontano E; Wöhrl BM
Nucleic Acids Res; 2016 Mar; 44(5):2310-22. PubMed ID: 26850643
[TBL] [Abstract][Full Text] [Related]
27. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.
Shaw-Reid CA; Feuston B; Munshi V; Getty K; Krueger J; Hazuda DJ; Parniak MA; Miller MD; Lewis D
Biochemistry; 2005 Feb; 44(5):1595-606. PubMed ID: 15683243
[TBL] [Abstract][Full Text] [Related]
28. A pyrophosphatase activity associated with purified HIV-1 particles.
Ducloux C; Mougel M; Goldschmidt V; Didierlaurent L; Marquet R; Isel C
Biochimie; 2012 Dec; 94(12):2498-507. PubMed ID: 22766015
[TBL] [Abstract][Full Text] [Related]
29. Phosphorylation of AZT-resistant human immunodeficiency virus type 1 reverse transcriptase by casein kinase II in vitro: effects on inhibitor sensitivity.
Lazaro JB; Boretto J; Selmi B; Capony JP; Canard B
Biochem Biophys Res Commun; 2000 Aug; 275(1):26-32. PubMed ID: 10944435
[TBL] [Abstract][Full Text] [Related]
30. The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1.
Sluis-Cremer N; Arion D; Parikh U; Koontz D; Schinazi RF; Mellors JW; Parniak MA
J Biol Chem; 2005 Aug; 280(32):29047-52. PubMed ID: 15970587
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
[TBL] [Abstract][Full Text] [Related]
32. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.
Boyer PL; Das K; Arnold E; Hughes SH
Antimicrob Agents Chemother; 2015 Dec; 59(12):7184-96. PubMed ID: 26324274
[TBL] [Abstract][Full Text] [Related]
34. Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses.
Jeffrey JL; Feng JY; Qi CC; Anderson KS; Furman PA
J Biol Chem; 2003 May; 278(21):18971-9. PubMed ID: 12651859
[TBL] [Abstract][Full Text] [Related]
35. Effects of beta-L-3'-azido-3'-deoxythymidine 5'-triphosphate on host and viral DNA polymerases.
Faraj A; El Alaoui AM; Gosselin G; Imbach JL; Morrow C; Sommadossi JP
Antiviral Res; 2000 Aug; 47(2):97-102. PubMed ID: 10996397
[TBL] [Abstract][Full Text] [Related]
36. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase.
Meyer PR; Matsuura SE; Mian AM; So AG; Scott WA
Mol Cell; 1999 Jul; 4(1):35-43. PubMed ID: 10445025
[TBL] [Abstract][Full Text] [Related]
37. Intracellular substrates for the primer-unblocking reaction by human immunodeficiency virus type 1 reverse transcriptase: detection and quantitation in extracts from quiescent- and activated-lymphocyte subpopulations.
Smith AJ; Meyer PR; Asthana D; Ashman MR; Scott WA
Antimicrob Agents Chemother; 2005 May; 49(5):1761-9. PubMed ID: 15855493
[TBL] [Abstract][Full Text] [Related]
38. A new strategy to inhibit the excision reaction catalysed by HIV-1 reverse transcriptase: compounds that compete with the template-primer.
Cruchaga C; Anso E; Font M; Martino VS; Rouzaut A; Martinez-Irujo JJ
Biochem J; 2007 Jul; 405(1):165-71. PubMed ID: 17355225
[TBL] [Abstract][Full Text] [Related]
39. Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays.
Gu Z; Quan Y; Li Z; Arts EJ; Wainberg MA
J Biol Chem; 1995 Dec; 270(52):31046-51. PubMed ID: 8537362
[TBL] [Abstract][Full Text] [Related]
40. A rapid phenotypic assay for detecting multiple nucleoside analogue reverse transcriptase inhibitor-resistant HIV-1 in plasma.
Qari SH; Winters M; Vandamme AM; Merigan T; Heneine W
Antivir Ther; 2002 Jun; 7(2):131-9. PubMed ID: 12212925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
